Profile Picture
Rewards
  • Search
  • Chat
  • Images
  • Videos
  • Maps
  • News
  • Shopping
  • More
    • Flights
    • Travel
    • Hotels
  • Top stories
  • Sports
  • U.S.
  • Local
  • World
  • Science
  • Technology
  • Entertainment
  • Politics
  • Business

Trending on Bing

'Never insult Poles again'
Announce engagement
'Right choice for our family'
Reportedly dating
Life on Jupiter's icy moon?
New Jersey home explosion
IN baby suffer 50+ rat bites
Continue to fuel rumors
Heroin found in diaper bag
Accepts humanitarian award
Okefenokee Swamp on list?
Rodgers making progress
Hit with $400 million fine
EEOC sues UPS
Taiwan factory fire kills 5
Fined $6 million by SEC
Wants to meet with Biden
Third GOP debate
Won’t be joining the military
Students abducted in Nigeria
Breaks his silence
$100K worth equipment stolen
Biologists to help tortoise
Homicides rise in Costa Rica
Sees franchise low opening
8 mummies uncovered
Unveils new gun safety office
Confirm romance with kiss
1st maternal RSV vaccine
Joins 40-40 club
  • Any time
    • Past hour
    • Past 24 hours
    • Past 7 days
    • Past 30 days
  • Best match
    • Most recent
209,000 results
朝日新聞社8d
Alzheimer’s drug Leqembi has full FDA approval
Alzheimer’s drug Leqembi has full FDA approval THE ASSOCIATED PRESS July 7, 2023 at 07:30 ... WASHINGTON--U.S. officials granted full approval to a closely watched Alzheimer’s drug on ...
Afro11d
Why is Medicare rationing Alzheimer’s drugs?
The FDA has recently approved exciting new treatments that can slow the progression of Alzheimer’s disease, a scourge that claims more American lives than breast cancer and prostate cancer combined.
10don MSN
Navigating new Alzheimer's drugs can be confusing and expensive. So do they really help patients?
Fast-track approval of three risky drugs intends to slow the disease, but evidence they benefit patients is shaky ...
3d
MIT’s A11 Drug: Reducing Inflammation and Enhancing Memory in Alzheimer’s Disease
A potential new Alzheimer’s drug represses the harmful inflammatory response of the brain’s immune cells, reducing disease ...
16hon MSN
FDA advisory panel rejects drug-device combination to treat Type 2 diabetes
The vote essentially upheld the Food and Drug Administration’s earlier rulings, with some members calling for new clinical ...
1d
At special FDA hearing, Intarcia's twice-rejected drug-device combo gets another 'no'
An advisory committee to the U.S. Food and Drug Administration unanimously rejected a drug-and-device combination made by a Boston biotech, which the agency had already rejected twice.
PBS11d
All You Need to Know About Alzheimer's
Use one of the services below to sign in to PBS: You've just tried to add this video to My List. But first, we need you to sign in to PBS using one of the services below. You've just tried to add ...
WTOP News9d
New Treatments for Alzheimer’s Disease
For anyone who has or knows someone who has Alzheimer’s disease, a progressive and irreversible form of dementia that’s ultimately deadly, it can sometimes be difficult to find hope.
BioPharma Dive
1d
Intarcia’s diabetes drug-device combo voted down again by FDA panel
The 19-member advisory committee unanimously voted against Intarcia in the review, citing cardiovascular and kidney safety concerns.
BioPharma Dive
10d
New startup Arialys takes aim at the immune system, hoping to create neuropsychiatry drugs
Arialys Therapeutics launched Tuesday with $58 million in funding from a group of life sciences investors that includes Johnson & Johnson’s venture arm.
Washington Monthly
10d
As Dementia Cases Soar, Who Will Care for the Caregivers?
A CMS pilot project will test a low-cost way to help families support a suffering loved one. It’s more promising than ...
Ravalli Republic
11d
FDA approves updated COVID vaccines to rev up protection this fall
The U.S. approved updated COVID-19 vaccines Monday, hoping to rev up protection against the latest coronavirus strains and ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results
© 2023 Microsoft
  • Privacy and Cookies
  • Legal
  • Advertise
  • About our ads
  • Help
  • Feedback
  • Your Privacy Choices